Levi & Korsinsky, LLP announces that an ARDX class action lawsuit has been filed on behalf of investors who purchased Ardelyx Inc. (ARDX) securities between August 6, 2020, and July 19, 2021.  For more on the ARDX Lawsuit please contact us today.

According to the Ardelyx lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint: Defendants made materially false and misleading statements regarding tenapanor and the likelihood that it would be approved by the Food and Drug Administration (“FDA”). Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug’s treatment effect, making it foreseeably likely that the FDA would not approve the drug.

TO LEARN MORE ABOUT THE ARDX CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Ardelyx you have until September 28, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com